Bio Rad Labs Inc Financials
Bio Rad Labs Inc (BIO) reported $2.6B in revenue for fiscal year 2025, up 0.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Stable gross economics are being overshadowed by overhead pressure and non-operating earnings swings, while cash generation stays intact.
FY2025 returned to$760M of net income even as operating margin sat at just1.8% , so the earnings recovery did not come from a stronger core engine. With operating cash flow at$532M and free cash flow at$375M , the business still converted operations into cash, implying the biggest profit swings are happening below the operating line rather than inside everyday operations.
Gross margin only eased from about
Capex of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bio Rad Labs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bio Rad Labs Inc has an operating margin of 1.8%, meaning the company retains $2 of operating profit per $100 of revenue. This results in a moderate score of 58/100, indicating healthy but not exceptional operating efficiency. This is down from 10.5% the prior year.
Bio Rad Labs Inc's revenue grew a modest 0.7% year-over-year to $2.6B. This slow but positive growth earns a score of 27/100.
Bio Rad Labs Inc has elevated debt relative to equity (D/E of 0.16), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 19/100, reflecting increased financial risk.
With a current ratio of 5.62, Bio Rad Labs Inc holds $5.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 92/100.
Bio Rad Labs Inc converts 14.5% of revenue into free cash flow ($374.6M). This strong cash generation earns a score of 73/100.
Bio Rad Labs Inc's ROE of 10.2% shows moderate profitability relative to equity, earning a score of 46/100. This is up from -28.1% the prior year.
Bio Rad Labs Inc scores 3.56, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($10.2B) relative to total liabilities ($3.1B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bio Rad Labs Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Bio Rad Labs Inc generates $0.70 in operating cash flow ($532.2M OCF vs $759.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Bio Rad Labs Inc earns $0.96 in operating income for every $1 of interest expense ($47.2M vs $49.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Bio Rad Labs Inc generated $2.6B in revenue in fiscal year 2025. This represents an increase of 0.7% from the prior year.
Bio Rad Labs Inc's EBITDA was $212.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 49.5% from the prior year.
Bio Rad Labs Inc reported $759.9M in net income in fiscal year 2025. This represents an increase of 141.2% from the prior year.
Bio Rad Labs Inc earned $27.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 142.6% from the prior year.
Cash & Balance Sheet
Bio Rad Labs Inc generated $374.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 29.4% from the prior year.
Bio Rad Labs Inc held $529.8M in cash against $1.2B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Bio Rad Labs Inc's gross margin was 51.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.
Bio Rad Labs Inc's operating margin was 1.8% in fiscal year 2025, reflecting core business profitability. This is down 8.7 percentage points from the prior year.
Bio Rad Labs Inc's net profit margin was 29.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 101.3 percentage points from the prior year.
Bio Rad Labs Inc's ROE was 10.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 38.3 percentage points from the prior year.
Capital Allocation
Bio Rad Labs Inc invested $275.6M in research and development in fiscal year 2025. This represents a decrease of 6.9% from the prior year.
Bio Rad Labs Inc spent $295.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 45.1% from the prior year.
Bio Rad Labs Inc invested $157.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 4.8% from the prior year.
BIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B+0.7% | $2.6B-3.9% | $2.7B-4.7% | $2.8B-4.1% | $2.9B+14.8% | $2.5B+10.1% | $2.3B+1.0% | $2.3B+6.0% | $2.2B+4.4% | $2.1B+2.4% | $2.0B-7.2% | $2.2B+2.0% | $2.1B+3.1% | $2.1B-0.2% | $2.1B |
| Cost of Revenue | $1.2B | $1.2B+4.7% | $1.2B-4.6% | $1.2B+0.8% | $1.2B-3.9% | $1.3B+16.0% | $1.1B+5.0% | $1.1B-1.1% | $1.1B+9.6% | $972.5M+4.6% | $929.7M+3.6% | $897.8M-9.9% | $996.5M+4.4% | $954.2M+4.4% | $914.1M+2.2% | $894.7M |
| Gross Profit | $1.3B | $1.3B-2.8% | $1.4B-3.4% | $1.4B-9.0% | $1.6B-4.3% | $1.6B+13.9% | $1.4B+14.4% | $1.3B+2.8% | $1.2B+3.0% | $1.2B+4.3% | $1.1B+1.5% | $1.1B-4.8% | $1.2B0.0% | $1.2B+2.0% | $1.2B-2.0% | $1.2B |
| R&D Expenses | $265.7M | $275.6M-6.9% | $295.9M+19.6% | $247.4M-3.7% | $256.9M-1.4% | $260.6M+19.7% | $217.8M+7.4% | $202.7M+1.8% | $199.2M-20.4% | $250.2M+21.6% | $205.7M+6.6% | $193.0M-12.4% | $220.3M+4.4% | $211.0M+0.8% | $209.2M+17.8% | $177.6M |
| SG&A Expenses | $852.2M | $844.3M+3.7% | $814.0M-3.3% | $841.7M+1.7% | $827.8M-5.6% | $877.1M+9.8% | $798.8M-3.1% | $824.6M-1.2% | $834.8M+3.5% | $806.8M-1.0% | $814.7M+6.9% | $762.0M-5.7% | $808.2M+1.3% | $798.1M+17.1% | $681.8M-2.0% | $696.0M |
| Operating Income | $53.1M | $47.2M-82.5% | $269.0M-20.4% | $337.8M-30.0% | $482.6M-3.5% | $500.3M+18.8% | $421.3M+83.5% | $229.7M+322.2% | -$103.3M-186.7% | $119.3M+114.0% | $55.7M-66.6% | $166.7M+11.2% | $150.0M-11.5% | $169.5M-35.9% | $264.2M-13.5% | $305.2M |
| Interest Expense | $48.8M | $49.0M+0.2% | $48.9M-1.0% | $49.4M+29.7% | $38.1M+2356.5% | $1.6M-92.9% | $21.9M-6.6% | $23.4M-2.3% | $24.0M+4.1% | $23.0M-1.6% | $23.4M+7.8% | $21.7M-2.0% | $22.1M-63.9% | $61.3M+19.9% | $51.1M-3.8% | $53.1M |
| Income Tax | $128.0M | $235.6M+147.3% | -$498.3M-134.2% | -$212.8M+80.2% | -$1.1B-190.1% | $1.2B+8.2% | $1.1B+119.7% | $502.4M+241.7% | $147.0M+701.6% | -$24.4M-257.1% | $15.6M-57.5% | $36.6M-14.3% | $42.7M+23.5% | $34.6M-46.3% | $64.4M-4.0% | $67.0M |
| Net Income | $222.4M | $759.9M+141.2% | -$1.8B-189.4% | -$637.3M+82.4% | -$3.6B-185.3% | $4.3B+11.5% | $3.8B+116.9% | $1.8B+381.0% | $365.6M+199.1% | $122.2M+370.2% | $26.0M-76.2% | $109.2M+23.0% | $88.8M+14.2% | $77.8M-53.0% | $165.5M-7.6% | $179.0M |
| EPS (Diluted) | — | $27.85+142.6% | -$65.36-199.5% | -$21.82+82.1% | -$121.79-186.5% | $140.83+11.4% | $126.47+117.0% | $58.27+381.6% | $12.10+197.3% | $4.07+362.5% | $0.88-76.3% | $3.71+21.6% | $3.05+13.4% | $2.69-53.5% | $5.78-8.1% | $6.29 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.6B+12.9% | $9.4B-23.9% | $12.3B-8.9% | $13.5B-24.1% | $17.8B+37.2% | $13.0B+62.0% | $8.0B+42.7% | $5.6B+31.3% | $4.3B+11.0% | $3.9B+3.8% | $3.7B+11.0% | $3.3B-1.4% | $3.4B-1.6% | $3.4B+11.2% | $3.1B |
| Current Assets | $2.9B-4.1% | $3.0B-0.6% | $3.0B-3.5% | $3.2B+58.7% | $2.0B-7.0% | $2.1B-1.8% | $2.2B+7.7% | $2.0B+2.4% | $2.0B+7.2% | $1.8B+3.8% | $1.8B+3.6% | $1.7B-2.3% | $1.8B-9.3% | $1.9B+7.7% | $1.8B |
| Cash & Equivalents | $529.8M+8.5% | $488.1M+20.9% | $403.8M-7.0% | $434.2M-7.8% | $470.8M-28.9% | $662.2M+0.2% | $660.7M+53.1% | $431.5M+12.4% | $383.8M-15.9% | $456.3M-0.3% | $457.5M+10.7% | $413.3M+24.6% | $331.6M-28.5% | $463.4M-19.3% | $574.2M |
| Inventory | $740.7M-2.5% | $760.0M-2.6% | $780.5M+8.5% | $719.3M+25.7% | $572.2M-8.0% | $622.3M+12.3% | $554.0M-5.1% | $583.8M-1.8% | $594.8M+13.3% | $525.0M+7.1% | $490.2M+4.1% | $471.0M-8.8% | $516.2M+13.4% | $455.1M+5.0% | $433.5M |
| Accounts Receivable | $460.6M+1.8% | $452.5M-7.5% | $489.0M-1.1% | $494.6M+16.8% | $423.5M+1.0% | $419.4M+6.8% | $392.7M+0.1% | $392.4M-15.6% | $464.8M+24.8% | $372.3M-4.9% | $391.5M+3.7% | $377.6M-10.7% | $422.7M+6.0% | $398.7M0.0% | $398.7M |
| Goodwill | $579.8M+41.2% | $410.5M-0.7% | $413.6M+1.7% | $406.5M+17.0% | $347.3M+19.0% | $291.9M+10.5% | $264.1M+20.2% | $219.8M-56.6% | $506.1M+6.1% | $477.1M-3.8% | $495.9M-0.9% | $500.4M-3.4% | $517.8M+4.5% | $495.4M+5.7% | $468.9M |
| Total Liabilities | $3.1B+11.7% | $2.8B-21.4% | $3.6B-8.5% | $3.9B-5.5% | $4.1B+33.0% | $3.1B+37.2% | $2.3B+41.7% | $1.6B+18.5% | $1.3B+5.6% | $1.3B+4.3% | $1.2B+5.5% | $1.2B-3.8% | $1.2B-15.8% | $1.4B+5.6% | $1.4B |
| Current Liabilities | $517.0M+10.5% | $467.8M-10.5% | $522.8M-8.1% | $568.7M-16.5% | $680.9M+7.8% | $631.5M-30.3% | $905.5M+100.9% | $450.8M-10.3% | $502.7M+6.7% | $471.3M+6.8% | $441.4M-1.2% | $446.8M-8.4% | $487.5M+3.2% | $472.4M+2.9% | $459.1M |
| Long-Term Debt | $1.2B+0.1% | $1.2B+0.1% | $1.2B+0.1% | $1.2B+11291.5% | $10.5M-14.2% | $12.3M-9.7% | $13.6M-96.9% | $438.9M+1.0% | $434.6M+0.1% | $434.2M+0.1% | $433.9M-0.4% | $435.7M0.0% | $435.6M-40.5% | $732.4M+0.1% | $731.7M |
| Total Equity | $7.5B+13.5% | $6.6B-24.8% | $8.7B-9.1% | $9.6B-29.7% | $13.7B+38.4% | $9.9B+71.8% | $5.8B+43.2% | $4.0B+37.2% | $2.9B+13.6% | $2.6B+3.8% | $2.5B+13.8% | $2.2B-0.1% | $2.2B+8.5% | $2.0B+15.5% | $1.7B |
| Retained Earnings | $8.2B+10.2% | $7.4B-19.9% | $9.3B-6.4% | $9.9B-26.8% | $13.5B+45.9% | $9.3B+69.4% | $5.5B+47.0% | $3.7B+103.3% | $1.8B+0.1% | $1.8B+1.1% | $1.8B+6.7% | $1.7B+5.5% | $1.6B+5.1% | $1.5B+12.4% | $1.4B |
BIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $492.6M | $532.2M+16.9% | $455.2M+21.4% | $374.9M+92.8% | $194.4M-71.0% | $669.5M+14.4% | $585.0M+27.8% | $457.9M+60.4% | $285.5M+174.2% | $104.1M-51.8% | $216.1M+16.0% | $186.2M-31.9% | $273.3M+61.6% | $169.1M-36.5% | $266.5M+1.4% | $262.7M |
| Capital Expenditures | $139.5M | $157.6M-4.8% | $165.6M+5.7% | $156.7M+38.9% | $112.8M-15.7% | $133.7M+23.2% | $108.6M+10.2% | $98.5M-24.1% | $129.8M+16.6% | $111.3M-21.3% | $141.4M+26.3% | $112.0M-7.4% | $121.0M+13.4% | $106.7M-25.3% | $142.9M+38.9% | $102.9M |
| Free Cash Flow | $353.1M | $374.6M+29.4% | $289.6M+32.7% | $218.2M+167.4% | $81.6M-84.8% | $535.7M+12.4% | $476.4M+32.6% | $359.4M+130.9% | $155.7M+2263.6% | -$7.2M-109.6% | $74.6M+0.6% | $74.2M-51.3% | $152.3M+143.8% | $62.5M-49.5% | $123.6M-22.7% | $159.8M |
| Investing Cash Flow | -$237.1M | -$189.7M-18.4% | -$160.2M-893.1% | $20.2M+101.7% | -$1.2B-51.4% | -$797.4M-1040.8% | -$69.9M+66.5% | -$208.9M-11.7% | -$187.0M-6.5% | -$175.6M+17.9% | -$213.9M-28.2% | -$166.9M+12.4% | -$190.5M-20830.3% | $919K+100.2% | -$400.4M-3.6% | -$386.3M |
| Financing Cash Flow | -$120.8M | -$283.2M-29.4% | -$218.8M+48.6% | -$425.6M-143.7% | $973.6M+1856.5% | -$55.4M+89.4% | -$523.0M-2198.3% | -$22.8M+53.2% | -$48.7M-14375.7% | $341K-96.2% | $9.0M+5.1% | $8.6M-26.6% | $11.7M+103.8% | -$311.7M-2576.1% | $12.6M+105.9% | -$213.6M |
| Share Buybacks | $132.7M | $295.5M+45.1% | $203.6M-52.5% | $428.7M+98.7% | $215.7M+331.4% | $50.0M-50.0% | $100.0M+257.2% | $28.0M-42.8% | $48.9M+1575.1% | $2.9M | $0 | $0 | $0 | $0-100.0% | $101K | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.9%-1.9pp | 53.7%+0.3pp | 53.4%-2.5pp | 55.9%-0.1pp | 56.0%-0.4pp | 56.5%+2.1pp | 54.4%+0.9pp | 53.4%-1.5pp | 55.0%-0.1pp | 55.0%-0.5pp | 55.5%+1.4pp | 54.2%-1.1pp | 55.3%-0.6pp | 55.8%-1.0pp | 56.9% |
| Operating Margin | 1.8%-8.7pp | 10.5%-2.2pp | 12.7%-4.6pp | 17.2%+0.1pp | 17.1%+0.6pp | 16.6%+6.6pp | 9.9%+14.4pp | -4.5%-10.0pp | 5.5%+2.8pp | 2.7%-5.6pp | 8.3%+1.4pp | 6.9%-1.0pp | 8.0%-4.8pp | 12.8%-1.9pp | 14.7% |
| Net Margin | 29.4%+101.3pp | -71.9%-48.0pp | -23.9% | -129.4% | 145.6% | 149.8% | 76.1%+60.1pp | 16.0%+10.3pp | 5.7%+4.4pp | 1.3%-4.2pp | 5.4%+1.3pp | 4.1%+0.4pp | 3.6%-4.4pp | 8.0%-0.6pp | 8.6% |
| Return on Equity | 10.2%+38.3pp | -28.1%-20.8pp | -7.3%+30.4pp | -37.7%-68.8pp | 31.1%-7.5pp | 38.6%+8.0pp | 30.6%+21.5pp | 9.1%+4.9pp | 4.2%+3.2pp | 1.0%-3.4pp | 4.4%+0.3pp | 4.1%+0.5pp | 3.6%-4.7pp | 8.2%-2.0pp | 10.3% |
| Return on Assets | 7.2%+26.9pp | -19.7%-14.5pp | -5.2%+21.7pp | -26.9%-50.8pp | 23.9%-5.5pp | 29.4%+7.4pp | 22.0%+15.4pp | 6.5%+3.7pp | 2.9%+2.2pp | 0.7%-2.3pp | 2.9%+0.3pp | 2.7%+0.4pp | 2.3%-2.5pp | 4.8%-1.0pp | 5.8% |
| Current Ratio | 5.62-0.9x | 6.48+0.6x | 5.83+0.3x | 5.55+2.6x | 2.92-0.5x | 3.39+1.0x | 2.41-2.1x | 4.49+0.6x | 3.930.0x | 3.91-0.1x | 4.03+0.2x | 3.84+0.2x | 3.61-0.5x | 4.10+0.2x | 3.92 |
| Debt-to-Equity | 0.160.0x | 0.180.0x | 0.140.0x | 0.12+0.1x | 0.000.0x | 0.000.0x | 0.00-0.1x | 0.110.0x | 0.150.0x | 0.170.0x | 0.170.0x | 0.200.0x | 0.20-0.2x | 0.36-0.1x | 0.42 |
| FCF Margin | 14.5%+3.2pp | 11.3%+3.1pp | 8.2%+5.3pp | 2.9%-15.4pp | 18.3%-0.4pp | 18.7%+3.2pp | 15.6%+8.8pp | 6.8%+7.1pp | -0.3%-3.9pp | 3.6%-0.1pp | 3.7%-3.3pp | 7.0%+4.1pp | 2.9%-3.0pp | 6.0%-1.7pp | 7.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Where Bio Rad Labs Inc Ranks
Frequently Asked Questions
What is Bio Rad Labs Inc's annual revenue?
Bio Rad Labs Inc (BIO) reported $2.6B in total revenue for fiscal year 2025. This represents a 0.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bio Rad Labs Inc's revenue growing?
Bio Rad Labs Inc (BIO) revenue grew by 0.7% year-over-year, from $2.6B to $2.6B in fiscal year 2025.
Is Bio Rad Labs Inc profitable?
Yes, Bio Rad Labs Inc (BIO) reported a net income of $759.9M in fiscal year 2025, with a net profit margin of 29.4%.
What is Bio Rad Labs Inc's EBITDA?
Bio Rad Labs Inc (BIO) had EBITDA of $212.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bio Rad Labs Inc have?
As of fiscal year 2025, Bio Rad Labs Inc (BIO) had $529.8M in cash and equivalents against $1.2B in long-term debt.
What is Bio Rad Labs Inc's gross margin?
Bio Rad Labs Inc (BIO) had a gross margin of 51.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bio Rad Labs Inc's operating margin?
Bio Rad Labs Inc (BIO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bio Rad Labs Inc's net profit margin?
Bio Rad Labs Inc (BIO) had a net profit margin of 29.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bio Rad Labs Inc's return on equity (ROE)?
Bio Rad Labs Inc (BIO) has a return on equity of 10.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bio Rad Labs Inc's free cash flow?
Bio Rad Labs Inc (BIO) generated $374.6M in free cash flow during fiscal year 2025. This represents a 29.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bio Rad Labs Inc's operating cash flow?
Bio Rad Labs Inc (BIO) generated $532.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bio Rad Labs Inc's total assets?
Bio Rad Labs Inc (BIO) had $10.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bio Rad Labs Inc's capital expenditures?
Bio Rad Labs Inc (BIO) invested $157.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bio Rad Labs Inc spend on research and development?
Bio Rad Labs Inc (BIO) invested $275.6M in research and development during fiscal year 2025.
What is Bio Rad Labs Inc's current ratio?
Bio Rad Labs Inc (BIO) had a current ratio of 5.62 as of fiscal year 2025, which is generally considered healthy.
What is Bio Rad Labs Inc's debt-to-equity ratio?
Bio Rad Labs Inc (BIO) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bio Rad Labs Inc's return on assets (ROA)?
Bio Rad Labs Inc (BIO) had a return on assets of 7.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bio Rad Labs Inc's Altman Z-Score?
Bio Rad Labs Inc (BIO) has an Altman Z-Score of 3.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bio Rad Labs Inc's Piotroski F-Score?
Bio Rad Labs Inc (BIO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio Rad Labs Inc's earnings high quality?
Bio Rad Labs Inc (BIO) has an earnings quality ratio of 0.70x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bio Rad Labs Inc cover its interest payments?
Bio Rad Labs Inc (BIO) has an interest coverage ratio of 0.96x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bio Rad Labs Inc?
Bio Rad Labs Inc (BIO) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.